A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

BACKGROUND: This exploratory study evaluated the safety/efficacy of nintedanib or sunitinib as first-line therapy in patients with advanced renal cell carcinoma (RCC). METHODS: Ninety-six patients were randomised (2:1) to either nintedanib (200 mg twice daily) or sunitinib (50 mg kg(−1) once daily (...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647871/
https://www.ncbi.nlm.nih.gov/pubmed/26448178
http://dx.doi.org/10.1038/bjc.2015.313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647871/
https://www.ncbi.nlm.nih.gov/pubmed/26448178
http://dx.doi.org/10.1038/bjc.2015.313

Ejemplares similares